HER2 IHC Introduction (What it is)
HER2 IHC is a laboratory test that measures HER2 protein on the surface of tumor cells.
It uses immunohistochemistry (IHC), a staining method performed on a tissue sample under a microscope.
HER2 IHC is commonly used in cancers where HER2 status can affect diagnosis and treatment planning.
It is most widely discussed in breast cancer, and it is also used in some other solid tumors.
Why HER2 IHC used (Purpose / benefits)
HER2 (human epidermal growth factor receptor 2) is a protein involved in cell growth signaling. In some cancers, tumor cells produce too much HER2 (often called “HER2 overexpression”), which can be linked to more aggressive tumor behavior and, importantly, to eligibility for certain targeted therapies.
The main purpose of HER2 IHC is to help the care team classify a tumor by HER2 status. That classification can influence:
- Treatment selection: Some systemic therapies are designed to target HER2 and are used only when the tumor meets specific HER2 criteria.
- Care planning: HER2 status is often integrated with other markers (such as hormone receptors in breast cancer) to build a more complete tumor profile.
- Consistency and standardization: HER2 IHC provides a widely used, relatively accessible method to assess HER2 in routine pathology workflows.
- Triage for additional testing: When HER2 IHC results are borderline or unclear, they can guide whether confirmatory testing (such as in situ hybridization) is needed.
In general terms, HER2 IHC helps solve the clinical problem of matching tumor biology to appropriate therapy options. It is not a screening test for the general public; it is a diagnostic and predictive test performed on known or suspected cancer tissue.
Indications (When oncology clinicians use it)
Oncology clinicians typically use HER2 IHC in situations such as:
- A new diagnosis of a cancer type where HER2 status is routinely assessed (commonly breast cancer; also used in some other solid tumors depending on guidelines)
- Evaluation of a recurrent tumor or metastatic disease where HER2 status may guide systemic therapy options
- Cases where prior HER2 results are unavailable, incomplete, or performed on a different specimen
- Situations where the tumor’s microscopic appearance and clinical context suggest that HER2 characterization could be relevant
- Treatment planning meetings (tumor boards) where biomarker status is needed to select or sequence therapies
- When considering clinical trials that require HER2 classification as an eligibility criterion
- When there is a reason to confirm the HER2 status due to changes in disease behavior or response patterns (varies by cancer type and stage)
Contraindications / when it’s NOT ideal
HER2 IHC is not “unsafe” in the way a medication or procedure can be, but it can be less suitable or less reliable in certain contexts. Situations where another material or approach may be better include:
- Insufficient or poor-quality tissue: Very small samples, crushed tissue, or samples with extensive necrosis (dead tissue) may not stain reliably.
- Suboptimal fixation/processing: How tissue is preserved and processed in the lab can affect staining quality and interpretation.
- Non-representative sampling: A biopsy may miss areas of the tumor that have different HER2 expression (tumor heterogeneity).
- Equivocal/borderline staining: Some results fall into an “uncertain” range and may require confirmatory testing with another method.
- Need to assess gene amplification directly: In some clinical scenarios, clinicians may prefer or require in situ hybridization (ISH) to evaluate HER2 gene changes rather than protein staining alone.
- Non-tissue situations: HER2 IHC generally requires tissue on a slide; it is not typically done as a blood test for routine treatment decision-making.
- Cancer types where HER2 testing is not standard: Depending on the tumor type, HER2 IHC may not be routinely recommended or may be used only in selected cases.
How it works (Mechanism / physiology)
HER2 IHC is a diagnostic pathology technique, not a treatment. It does not change the tumor biology; it measures a feature of tumor biology that may matter clinically.
The basic mechanism (diagnostic pathway)
- A tissue sample from a biopsy or surgery is processed and embedded in paraffin (a standard way pathology labs preserve tissue).
- Thin tissue sections are placed on slides.
- Antibodies designed to bind to the HER2 protein are applied to the slide.
- A detection system produces a colored reaction where HER2 is present, allowing the pathologist to see the pattern and intensity under a microscope.
- The pathologist assigns a score based on established scoring criteria for that cancer type.
Relevant tumor biology
- HER2 is a receptor involved in signaling pathways that can promote cell growth and survival.
- Tumors may show increased HER2 protein expression and/or HER2 gene amplification (extra copies of the HER2 gene). These are related but not identical concepts.
- HER2 IHC measures protein expression on tumor cell membranes (how much HER2 protein is present and how it appears), which can be associated with eligibility for HER2-directed therapies in certain cancers.
Onset, duration, and reversibility
These properties do not apply in the same way they would for a drug. HER2 IHC produces a result at a point in time based on the sampled tissue. However:
- HER2 expression can sometimes differ between the primary tumor and metastases, or change over time, depending on the cancer type and prior treatments.
- Because tumors can be heterogeneous, a result reflects the tested specimen and the tested area, not necessarily every tumor cell in the body.
HER2 IHC Procedure overview (How it’s applied)
HER2 IHC is best thought of as a lab test performed on tumor tissue, rather than a procedure a patient “receives” directly. The overall workflow usually fits into the broader cancer-care pathway:
- Evaluation/exam: A clinician evaluates symptoms, a lump, abnormal imaging, or other findings and determines whether tissue sampling is needed.
- Imaging/biopsy/labs: Imaging may guide a biopsy, or surgery may remove the tumor. Routine pathology confirms the diagnosis (for example, carcinoma) and identifies key features.
- Staging: Staging workup (which varies by cancer type and stage) helps determine how far the cancer has spread. HER2 testing is typically part of tumor characterization rather than staging itself, but the results are used alongside stage to plan care.
- Treatment planning: The pathology lab performs HER2 IHC on the tissue block or slides. A pathologist interprets the staining and issues a report that includes the HER2 IHC score and any notes about test quality or interpretation.
- Intervention/therapy: If HER2 status meets criteria relevant to that cancer type, the oncology team may discuss HER2-directed therapy options as part of systemic treatment planning (often alongside surgery, radiation, endocrine therapy, chemotherapy, immunotherapy, or combinations).
- Response assessment: Imaging, exams, and sometimes repeat biopsies are used to assess response to treatment. HER2 status is usually not “tracked” like a blood value, but it can be re-evaluated in selected circumstances (varies by clinician and case).
- Follow-up/survivorship: HER2 status remains part of the patient’s medical record and may inform future treatment choices if recurrence occurs or if new systemic options become relevant.
A common feature of HER2 IHC workflows is reflex testing: if the IHC result is borderline or uncertain, the lab may automatically perform (or the clinician may request) confirmatory testing with a different method, often ISH, to clarify HER2 status.
Types / variations
HER2 IHC has several practical variations, depending on the clinical setting and the question being asked:
- Cancer type–specific scoring frameworks: The way HER2 IHC is scored and interpreted can differ by cancer type (for example, breast versus gastric/GEJ), because staining patterns and clinically validated thresholds may differ.
- Diagnostic vs. re-testing in recurrence/metastasis: Testing may be done at initial diagnosis and repeated later on a metastatic site or recurrent tumor when clinically relevant.
- Core biopsy vs. surgical specimen: HER2 IHC can be performed on small biopsy samples or larger surgical resections. Larger samples may better capture tumor heterogeneity, while biopsies may be the only feasible option in some settings.
- Different laboratory platforms and antibody clones: Labs may use different validated reagents and automated stainers. Standardization and quality control aim to keep results comparable, but minor variability can occur.
- Reflex/confirmatory pathways: Borderline IHC results may lead to ISH testing for HER2 gene amplification, depending on the guideline framework used for that cancer type.
- HER2 expression spectrum reporting (where applicable): Some clinical discussions distinguish between clearly negative, equivocal, and positive categories, and in some contexts clinicians may also discuss lower levels of expression. The exact clinical meaning depends on the cancer type and available therapies.
Pros and cons
Pros:
- Helps classify tumors by a clinically relevant biomarker (HER2 protein expression)
- Uses widely available pathology methods and can often be done on routine biopsy or surgical tissue
- Can inform eligibility for HER2-directed targeted therapies in appropriate cancer types
- Generally integrates well with other pathology markers to build a comprehensive tumor profile
- Can prompt confirmatory testing when results are borderline, improving diagnostic confidence
- Supports standardized communication among oncology, surgery, pathology, and radiation teams
Cons:
- Requires adequate, well-processed tissue; sample quality can limit accuracy
- Interpretation can be affected by pre-analytic factors (fixation) and analytic factors (assay/platform differences)
- Tumor heterogeneity can lead to sampling-related uncertainty (one area may not represent the whole tumor)
- Some results are equivocal and require additional testing, which can add time and complexity
- HER2 IHC measures protein expression, which may not fully capture underlying gene changes in every case
- The clinical implications of a given score can vary by cancer type and available treatment options
Aftercare & longevity
Because HER2 IHC is a test rather than a treatment, “aftercare” mainly relates to how results are used and how they remain relevant over time.
What commonly affects the practical impact (“longevity”) of HER2 IHC results includes:
- Cancer type and stage: The role of HER2 status differs across diseases and clinical scenarios. Varies by cancer type and stage.
- Tumor biology beyond HER2: Other biomarkers and pathology features (such as hormone receptor status in breast cancer) influence treatment planning alongside HER2.
- Specimen factors: A result from a small biopsy may be less representative than a larger specimen in some cases, particularly when heterogeneity is suspected.
- Change over time: In some cancers, HER2 status may differ between the original tumor and later metastases, or after certain therapies. Whether and when to re-test varies by clinician and case.
- Treatment intensity and follow-up structure: If HER2-directed therapy is used, follow-up planning typically includes routine oncology monitoring for response and side effects based on the chosen regimen.
- Comorbidities and supportive care: Overall health, other medical conditions, and access to supportive services can influence the broader care journey, independent of HER2 testing.
Patients and learners often find it helpful to view HER2 IHC as one piece of a larger puzzle: it adds important information, but it is interpreted in context with clinical findings, imaging, stage, and other pathology results.
Alternatives / comparisons
HER2 IHC is one of several approaches to assessing HER2-related tumor biology. The most common comparisons are with tests that measure HER2 at the gene level or via broader molecular profiling.
HER2 IHC vs. in situ hybridization (ISH, including FISH and related methods)
- What they measure: HER2 IHC measures HER2 protein expression; ISH measures HER2 gene amplification (extra gene copies) in tumor cells.
- When used: ISH is commonly used as a confirmatory or “reflex” test when IHC results are equivocal, or when a gene-level answer is preferred by guideline or clinical context.
- Strengths/limits: ISH can clarify borderline cases, while IHC is often faster and more directly reflects protein expression patterns on the cell membrane. Each has potential technical limitations.
HER2 IHC vs. next-generation sequencing (NGS) and broader tumor profiling
- What they measure: NGS can detect multiple gene alterations at once (including changes involving ERBB2, the gene that encodes HER2), depending on the panel used.
- Clinical role: NGS may be used when treatment decisions require a broader view of tumor genetics, when standard markers are inconclusive, or for clinical trial matching. It is not a direct substitute for HER2 IHC in every cancer type because therapeutic criteria may be tied to specific test methods and validated thresholds.
- Practical considerations: NGS may require more tissue, more time, and different lab infrastructure than IHC.
HER2 IHC vs. observation/active surveillance and local therapies
Observation, surgery, and radiation are treatment strategies rather than biomarker tests, so the comparison is indirect. HER2 IHC does not replace these options; it helps characterize the tumor so that clinicians can decide whether systemic therapy (including targeted therapy) should be added to local approaches, depending on cancer type and stage.
Standard care vs. clinical trials (where applicable)
HER2 IHC results are often used to determine whether a person might be eligible for trials studying HER2-targeted approaches or novel combinations. Trial eligibility rules vary, and the required testing method and cutoffs may differ from routine practice.
HER2 IHC Common questions (FAQ)
Q: Is HER2 IHC the same as a genetic test?
HER2 IHC is not a genetic test in the usual sense. It measures the amount and pattern of HER2 protein on tumor cells using a stain viewed under a microscope. A different test, often in situ hybridization (ISH), is commonly used to assess HER2 gene amplification.
Q: Does HER2 IHC require a new biopsy?
Often it can be performed on tissue that was already collected during a prior biopsy or surgery. In some situations, a new biopsy may be considered if there is not enough tissue, if the sample quality is poor, or if clinicians need to test a metastatic site. Whether re-biopsy is needed varies by clinician and case.
Q: Is HER2 IHC painful or does it involve anesthesia?
HER2 IHC itself is done in the laboratory on tissue, so it does not cause pain. Any discomfort relates to how the tissue was obtained (for example, a needle biopsy or surgery). The type of anesthesia, if any, depends on the procedure used to collect the tissue.
Q: How long does it take to get HER2 IHC results?
Turnaround time varies by facility, workflow, and whether additional confirmatory testing is needed. Some results are available within days, while others may take longer if reflex testing or repeat staining is required. Your pathology report typically includes the final interpreted result once complete.
Q: What do HER2 IHC scores mean?
HER2 IHC is commonly reported using a scoring system that categorizes staining from negative to positive, with an intermediate/equivocal category in some frameworks. The exact interpretation and clinical implications depend on the cancer type and the guideline criteria used by the lab. When results are equivocal, another test may be used to clarify HER2 status.
Q: Can HER2 IHC be wrong?
Like all laboratory tests, HER2 IHC can be affected by tissue handling, staining technique, and interpretation, and tumors can be heterogeneous. Pathology labs use quality controls and standardized methods to reduce variability. When results are borderline or don’t fit the clinical picture, clinicians may consider confirmatory testing or repeat testing on another specimen.
Q: If my tumor is HER2-positive, does that change treatment options?
In several cancer types, HER2-positive status can make HER2-targeted therapies part of the treatment discussion. Treatment decisions still depend on many factors, including cancer type, stage, other biomarkers, overall health, and prior therapies. Only a treating oncology team can apply the result to an individual plan.
Q: Are there side effects from HER2 IHC testing?
HER2 IHC itself does not cause side effects because it is performed on a tissue slide in the lab. Side effects, if any, relate to the biopsy or surgical procedure used to obtain tissue, such as soreness, bruising, or procedural risks. Those risks vary with the biopsy site and technique.
Q: Will HER2 IHC affect my ability to work or do normal activities?
The test does not affect daily activities, but the tissue collection procedure might. Many biopsies allow return to usual activities relatively quickly, while surgery may require a longer recovery. Activity guidance should come from the procedural team based on what was done.
Q: How much does HER2 IHC cost?
Costs vary widely based on the health system, insurance coverage, region, and whether additional testing is required. HER2 IHC may be bundled into pathology charges for cancer diagnosis, or billed separately depending on the setting. For general planning, it’s reasonable to ask the care team or billing office about expected out-of-pocket costs.
Q: Does HER2 status relate to fertility or pregnancy?
HER2 IHC is a diagnostic test and does not affect fertility. However, if HER2 status leads to certain systemic therapies, fertility and pregnancy considerations may become part of treatment planning. These discussions are individualized and depend on the specific therapies, timing, and clinical goals.